Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease.

ABSTRACT:

Introduction

The coronavirus disease 2019 (COVID-19) pandemic is the largest public health challenge of the twenty-first century. While COVID-19 primarily affects the respiratory system, manifesting as interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also has implications for the cardiovascular system. Moreover, those admitted to hospital with severe COVID-19 are more likely to have cardiovascular comorbidities such as hypertension and diabetes mellitus. The underlying pathophysiology of why COVID-19 onset can further decline cardiac pathologies as well as trigger acute onset of new cardiac complications is not yet well understood.

Areas covered

In this review, the authors extensively review literature focused on the current understanding an

SUBMITTER: Khan M 

PROVIDER: S-EPMC8425433 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature